Scott Gettinger, MD
Medical Oncology · New Haven, CTNPI 1477541274
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,600 of the $5,221 with a category attached, or 88.1%. E.r. Squibb & Sons, L.L.C. accounts for 88.1% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $4,600 and has fallen 99.6% since, to $20 in 2025.
Across 8 payments — averaging $652.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$5K
- Jazz Pharmaceuticals Inc.$248
- Amgen$156
- Genentech USA, Inc.$138
- Janssen Scientific Affairs, LLC$78
Across 176 payments — averaging $28,909 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$2M
- Merck$1.9M
- Amgen$572K
- Iovance Biotherapeutics, Inc.$232K
- Takeda Pharmaceuticals U.S.A., Inc.$147K
- Genentech, Inc.$107K
- plus $98K from 2 others
What the payments were for
- Consulting fees$4,60088%
- Food & beverage$62112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $4,600 |
| Jazz Pharmaceuticals Inc. | 3 | $248 |
| Amgen | 2 | $156 |
| Genentech USA, Inc. | 1 | $138 |
| Janssen Scientific Affairs, LLC | 1 | $78 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPZELCA$129
How this compares
$5,221 in reported general payments places this provider in the 55th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 40 | $31,309 |
| Dexamethasone | 48 | $996 |
| Oxycodone Hcl | 23 | $557 |
| Prochlorperazine Maleate | 28 | $490 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $473 |
| Ondansetron OdtOndansetron | 22 | $402 |
| Pantoprazole Sodium | 13 | $133 |
| Prednisone | 25 | $67 |
| Folic Acid | 14 | $60 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $26 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in New Haven
- Peter MarksNew Haven$578K
- Daniel PetrylakNew Haven$446K
- Mandar MuzumdarNew Haven$371K
- Barbara BurtnessNew Haven$297K
- Ian KropNew Haven$219K
- Francine FossNew Haven$193K
- Anne ChiangNew Haven$158K
- Mario SznolNew Haven$157K
- Lajos PusztaiNew Haven$152K
- Howard HochsterNew Haven$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.